ArticleRheumatology international2019
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.
Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Longitudinal association between visceral adiposity index and arthritis-diabetes comorbidity risk: A cohort study from CHARLS.Medicine · 2026Article
- Janus Kinase Inhibitors and Body Weight: Current Evidence and Potential.Life (Basel, Switzerland) · 2026Review
- Review
- Article
- Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis.ACR open rheumatology · 2025Article
- Cardiovascular Risk Factor and Atherosclerosis in Rheumatoid Arthritis (RA).Current cardiology reports · 2025Review
- Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms.Frontiers in immunology · 2025Article
- Association Between the Quality of Life Domains with Anthropometric and Adiposity Indices in Rheumatoid Arthritis: A Cross-Sectional Study from a Single Centre in Erbil-Iraq.Mediterranean journal of rheumatology · 2024Article
- Weight gain secondary to the use of Janus kinase inhibitors.Archives of dermatological research · 2023Review
- JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.Journal of clinical medicine · 2023Review
- Real-life experience of tofacitinib in patients with treatment-resistant rheumatoid arthritis: A 5-year follow-up: Monocentric experience.Northern clinics of Istanbul · 2022Article
- Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.Frontiers in immunology · 2021Review
- The Impact of Obesity on Disease Activity and Treatment Response in Rheumatoid Arthritis.Current rheumatology reports · 2020Review
- The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition.Metabolites · 2020Review
- Emerging Topical and Systemic JAK Inhibitors in Dermatology.Frontiers in immunology · 2019Review
- A case series on tofacitinib-induced weight gain.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in cardiovascular risk in patients with rheumatoid arthritis (RA) compared with the general population is due to the combined effect of traditional risk factors for cardiovascular diseases, metabolic disorders, systemic inflammation, and side effects of antirheumatic drugs. Tofacitinib (TOFA) is an oral reversible inhibitor of janus kinases for the treatment of RA with proven efficacy and good tolerability, but its effects on body weight and metabolic profile need to be clarified. We investigated the effects of TOFA on body mass index (BMI) and visceral adiposity index (VAI) in RA patients. Thirty-one consecutive patients with active RA and starting new treatment with TOFA were included in a prospective 1 year follow-up observational study of cardiovascular effects of TOFA treatment. Weight, height, waist circumference, BMI, blood pressure, lipid profile, fasting glucose and VAI were measured at baseline and 12 months of treatment. Median weight gain was 3 kg (4.2%) after 1 year of TOFA. 23 (74%) patients suffered from a weight gain, and 6 (26%) out of them from a weight increment of 10% or more. Patients with lower BMI (p = 0.024) and higher baseline DAS28 [ESR] (p = 0.017) have the risk of an increase in BMI > 5% during TOFA treatment in a multivariate analysis. A decrease in VAI after 12 months was recorded. Weight increment and improvement of VAI are frequent on TOFA treatment. BMI dynamics associated with higher disease activity at baseline and lower baseline BMI.
Indexed as
Identifiers
31053871What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.